Compounds > metformin
Page last updated: 2024-10-30

metformin and Urinary Bladder Neoplasms

metformin has been researched along with Urinary Bladder Neoplasms in 46 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.

Research Excerpts

ExcerptRelevanceReference
"Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG."9.51Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022)
"The present meta-analysis indicated that metformin intake could improve the prognosis of bladder cancer patients."8.98Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chen, HQ; Chen, JB; Cui, Y; Hu, J; Liu, LF; Ren, WB; Zhou, X; Zhu, YW; Zu, XB, 2018)
"Studies have suggested a positive association between bladder cancer (BC) outcome and comedication use, including nonsteroidal anti-inflammatory drugs (NSAID), metformin, and prednisone use."8.31Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada. ( Aprikian, AG; Dragomir, A; Kassouf, W; O'Flaherty, A; Tanguay, S; Wissing, MD, 2023)
"Olaparib combined with metformin has better effects on the proliferation, clone formation, migration, invasion, and apoptosis of bladder cancer cells than single drug, indicating that metformin can enhance the inhibitory effect of olaparib on tumor growth and regulate the expression of STAT3/C-MYC signaling pathway proteins."8.12Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells. ( Chi, BJ; Quan, LL; Sun, Y; Wang, SQ; Wei, B; Zhao, JT, 2022)
"Metformin inhibited bladder cancer T24 and 5637 cell migration and proliferation, and induced their apoptosis."8.12Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway. ( Han, Y; Hao, L; He, X; Jia, B; Jiang, H; Li, X; Luo, D; Peng, Z; Shen, Z; Shi, J; Sima, C; Wang, K; Xue, D; Yang, D; Zhang, F; Zhang, J; Zhang, Q; Zhang, S; Zhong, Q, 2022)
"Metformin has been reported to function as the anti-tumor inhibiting the growth of different types of cancers, including bladder cancer."7.91Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells. ( Gao, S; Li, Y; Meng, X; Sun, X; Wang, B; Wang, G; Wang, Y; Wu, Y; Xie, J; Yan, X; Yin, B; Zhang, X; Zheng, Q, 2019)
"The purpose of the present study was to determine the potential relationships of glycemic control and use of metformin with non-muscle invasive bladder cancer characteristics."7.83Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. ( Ahn, JH; Hwang, EC; Jung, SI; Kim, SW; Kwon, DD; Yim, SU, 2016)
"The aim of this study was to look at the influence of metformin intake and duration, on urinary bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new user design (inception cohort)."7.81Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. ( Buntinx, F; De Bruin, ML; De Vries, F; Driessen, JH; Goossens, ME; Zeegers, MP, 2015)
"Whether metformin therapy affects bladder cancer risk in patients with type 2 diabetes mellitus (T2DM) has not been extensively investigated."7.80Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. ( Tseng, CH, 2014)
"Use of metformin is not associated with a decreased incidence of bladder cancer."7.80Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. ( Finkelman, BS; Haas, NB; Haynes, K; Keefe, SM; Lewis, JD; Mamtani, R; Pfanzelter, N; Vaughn, DJ; Wang, X, 2014)
" Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality."7.80Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014)
"To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007."7.79Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013)
"Non-muscle-invasive bladder cancer (NMIBC) is the most common neoplasm of the urinary tract and requires life-long invasive surveillance to detect disease recurrence."6.90Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. ( Boevé, ER; Brummelhuis, IS; de Reijke, TM; Molenaar, RJ; Oddens, JR; Pollak, MN; Savci-Heijink, CD; van der Meer, SA; van Hattum, JW; Wilmink, JW; Witjes, JF, 2019)
"Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG."5.51Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022)
"We found metformin inhibited bladder cancer cell proliferation in a dose- and time-dependent manner."5.46UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis. ( Jiang, X; Li, T; Sun, X, 2017)
"Metformin also can arrest bladder cancer cells in G1/S phases, which subsequently leads to apoptosis."5.43Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. ( Huang, Z; Jiang, J; Lan, W; Liu, G; Liu, Q; Tong, D; Xiao, H; Yang, J; Yuan, W; Zhang, D; Zhang, J; Zhang, Y, 2016)
" In contrast, oral treatment at a dose of 800mg/kg/d exhibited little efficacy whereas severe toxicity existed if the dosage is higher."5.43High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. ( Chen, AF; Cheng, Y; Guo, P; Huang, Y; Li, L; Li, X; Liu, Z; Lv, H; Peng, M; Su, Q; Tao, T; Tao, X; Xue, L; Yang, X; Zeng, Q, 2016)
"In addition, we observed that bladder cancer cell lines (RT4, UMUC-3, and J82) with homozygous deletion of either TSC1 or PTEN are more sensitive to metformin than those (TEU2, TCCSUP, and HT1376) with wild-type TSC1 and PTEN genes."5.43High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. ( Avizonis, D; Blair, CA; Li, X; Liu, Z; McClelland, M; Pollak, M; Uchio, E; Wu, XR; Yokoyama, NN; Youssef, R; Zi, X, 2016)
"Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs."5.43Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. ( Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X, 2016)
" We have also launched a study to combine metformin with the small molecule targeted drug gefitinib to treat bladder cancer using intravesical administration."5.01Novel application of metformin combined with targeted drugs on anticancer treatment. ( Deng, J; Peng, J; Peng, M; Wang, Z; Xiao, D; Yang, X; Zhou, S, 2019)
"The present meta-analysis indicated that metformin intake could improve the prognosis of bladder cancer patients."4.98Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chen, HQ; Chen, JB; Cui, Y; Hu, J; Liu, LF; Ren, WB; Zhou, X; Zhu, YW; Zu, XB, 2018)
" The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women."4.89[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013)
"According to our knowledge, we are the first to show, that combination of doxorubicin and metformin also worth considering in the treatment of bladder cancer."4.31Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells. ( Hałas-Wiśniewska, M; Izdebska, M; Mlicka, A; Mlicki, P; Niewiadomski, P; Zielińska, W, 2023)
"Studies have suggested a positive association between bladder cancer (BC) outcome and comedication use, including nonsteroidal anti-inflammatory drugs (NSAID), metformin, and prednisone use."4.31Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada. ( Aprikian, AG; Dragomir, A; Kassouf, W; O'Flaherty, A; Tanguay, S; Wissing, MD, 2023)
"Our previous study found that the intravesical perfusion of metformin has excellent inhibitory effects against bladder cancer (BC)."4.31Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration. ( Chen, X; Deng, J; Hu, X; Li, D; Peng, M; Xiao, D; Xie, L; Xie, Y; Yang, X; Zhang, X, 2023)
"Metformin inhibited bladder cancer T24 and 5637 cell migration and proliferation, and induced their apoptosis."4.12Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway. ( Han, Y; Hao, L; He, X; Jia, B; Jiang, H; Li, X; Luo, D; Peng, Z; Shen, Z; Shi, J; Sima, C; Wang, K; Xue, D; Yang, D; Zhang, F; Zhang, J; Zhang, Q; Zhang, S; Zhong, Q, 2022)
"Olaparib combined with metformin has better effects on the proliferation, clone formation, migration, invasion, and apoptosis of bladder cancer cells than single drug, indicating that metformin can enhance the inhibitory effect of olaparib on tumor growth and regulate the expression of STAT3/C-MYC signaling pathway proteins."4.12Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells. ( Chi, BJ; Quan, LL; Sun, Y; Wang, SQ; Wei, B; Zhao, JT, 2022)
"Metformin has been reported to function as the anti-tumor inhibiting the growth of different types of cancers, including bladder cancer."3.91Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells. ( Gao, S; Li, Y; Meng, X; Sun, X; Wang, B; Wang, G; Wang, Y; Wu, Y; Xie, J; Yan, X; Yin, B; Zhang, X; Zheng, Q, 2019)
"The purpose of the present study was to determine the potential relationships of glycemic control and use of metformin with non-muscle invasive bladder cancer characteristics."3.83Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. ( Ahn, JH; Hwang, EC; Jung, SI; Kim, SW; Kwon, DD; Yim, SU, 2016)
"To study the effects of vitamin D3 combined with metformin on the proliferation and apoptosis in human bladder cancer cell line SW-780 and its possible mechanism."3.81Vitamin D3 enhances antitumor activity of metformin in human bladder carcinoma SW-780 cells. ( Chen, J; Gao, JM; Gao, MT; Guo, LS; Li, CY; Li, HX; Liang, JQ; Wang, QL; Wu, YJ; Zhang, SY, 2015)
"These findings provide for the first time the evidence that metformin can block precancerous lesions progressing to invasive tumors through inhibiting the activation of STAT3 pathway, and may be used for treatment of the non-invasive bladder cancers to prevent them from progression to invasive tumors."3.81Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways. ( Bo, JJ; Gao, JX; Huang, YR; Lin, SL; Liu, MY; Liu, N; Liu, Q; Liu, SS; Pan, Q; Shen, RL; Yang, GL; Yang, JH; Zhang, LH, 2015)
"The aim of this study was to look at the influence of metformin intake and duration, on urinary bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new user design (inception cohort)."3.81Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. ( Buntinx, F; De Bruin, ML; De Vries, F; Driessen, JH; Goossens, ME; Zeegers, MP, 2015)
"Use of metformin is not associated with a decreased incidence of bladder cancer."3.80Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. ( Finkelman, BS; Haas, NB; Haynes, K; Keefe, SM; Lewis, JD; Mamtani, R; Pfanzelter, N; Vaughn, DJ; Wang, X, 2014)
" Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality."3.80Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014)
"Whether metformin therapy affects bladder cancer risk in patients with type 2 diabetes mellitus (T2DM) has not been extensively investigated."3.80Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. ( Tseng, CH, 2014)
"To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007."3.79Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013)
" In BPH men, diabetes duration was not significantly related with bladder cancer; but metformin was consistently associated with a significantly lower risk, with adjusted hazard ratio of 0."3.79Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. ( Tseng, CH, 2013)
"Non-muscle-invasive bladder cancer (NMIBC) is the most common neoplasm of the urinary tract and requires life-long invasive surveillance to detect disease recurrence."2.90Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. ( Boevé, ER; Brummelhuis, IS; de Reijke, TM; Molenaar, RJ; Oddens, JR; Pollak, MN; Savci-Heijink, CD; van der Meer, SA; van Hattum, JW; Wilmink, JW; Witjes, JF, 2019)
"Bladder cancer is the most prevalent malignancy of the urinary tract and is associated with significant morbidity and mortality."2.58Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts. ( Khajeh, NR; Khoyilar, C; Spradling, K; Wu, Y; Youssef, RF; Zi, X, 2018)
"Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control."2.50Systematic reviews to ascertain the safety of diabetes medications. ( Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH, 2014)
"EMTs facilitate bladder cancer (BC) metastasis development, but the mechanism by which high-glucose levels promote these EMTs in BC remains unclear."1.56Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. ( Chen, H; Li, S; Lin, Q; Xia, J; Xu, R; Zhang, F; Zhu, H, 2020)
"PKM2 was overexpressed in bladder cancer cells and tissues, and down-regulation of PKM2 enhanced the sensitivity of THP in vitro."1.48Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer. ( Chen, AF; Darko, KO; Deng, J; He, S; Peng, M; Su, Q; Tang, L; Tao, T; Yang, X; Zeng, Q; Zhou, S, 2018)
"We found metformin inhibited bladder cancer cell proliferation in a dose- and time-dependent manner."1.46UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis. ( Jiang, X; Li, T; Sun, X, 2017)
" In contrast, oral treatment at a dose of 800mg/kg/d exhibited little efficacy whereas severe toxicity existed if the dosage is higher."1.43High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. ( Chen, AF; Cheng, Y; Guo, P; Huang, Y; Li, L; Li, X; Liu, Z; Lv, H; Peng, M; Su, Q; Tao, T; Tao, X; Xue, L; Yang, X; Zeng, Q, 2016)
"In addition, we observed that bladder cancer cell lines (RT4, UMUC-3, and J82) with homozygous deletion of either TSC1 or PTEN are more sensitive to metformin than those (TEU2, TCCSUP, and HT1376) with wild-type TSC1 and PTEN genes."1.43High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. ( Avizonis, D; Blair, CA; Li, X; Liu, Z; McClelland, M; Pollak, M; Uchio, E; Wu, XR; Yokoyama, NN; Youssef, R; Zi, X, 2016)
"Metformin also can arrest bladder cancer cells in G1/S phases, which subsequently leads to apoptosis."1.43Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. ( Huang, Z; Jiang, J; Lan, W; Liu, G; Liu, Q; Tong, D; Xiao, H; Yang, J; Yuan, W; Zhang, D; Zhang, J; Zhang, Y, 2016)
"Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs."1.43Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. ( Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X, 2016)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's30 (65.22)24.3611
2020's16 (34.78)2.80

Authors

AuthorsStudies
Klose, K1
Packeiser, EM1
Müller, P1
Granados-Soler, JL1
Schille, JT1
Goericke-Pesch, S1
Kietzmann, M1
Murua Escobar, H1
Nolte, I1
Yao, X1
Liu, H2
Xu, H1
Shen, Z4
Xue, D1
Wang, K1
Zhang, F3
Shi, J1
Jia, B4
Yang, D2
Zhang, Q3
Zhang, S3
Jiang, H1
Luo, D1
Li, X13
Zhong, Q1
Zhang, J5
Peng, Z1
Han, Y1
Sima, C1
He, X2
Hao, L1
Chi, BJ1
Sun, Y2
Quan, LL1
Zhao, JT1
Wei, B1
Wang, SQ1
Feng, Y3
Mlicka, A3
Mlicki, P3
Niewiadomski, P3
Zielińska, W3
Hałas-Wiśniewska, M3
Izdebska, M3
Dias, HF1
Mochizuki, Y1
Kühtreiber, WM1
Takahashi, H1
Zheng, H1
Faustman, DL1
Wissing, MD1
O'Flaherty, A1
Dragomir, A1
Tanguay, S1
Kassouf, W1
Aprikian, AG1
Fiala, O1
Buti, S1
Takeshita, H1
Okada, Y1
Massari, F1
Palacios, GA1
Dionese, M1
Scagliarini, S1
Büttner, T1
Fornarini, G1
Myint, ZW1
Galli, L1
Souza, VC1
Pichler, R1
De Giorgi, U1
Quiroga, MNG1
Gilbert, D1
Popovic, L1
Grande, E1
Mammone, G1
Berardi, R1
Crabb, SJ1
Molina-Cerrillo, J1
Freitas, M1
Luz, M1
Iacovelli, R1
Calabrò, F1
Tural, D1
Atzori, F1
Küronya, Z1
Chiari, R1
Campos, S1
Caffo, O1
Fay, AP1
Kucharz, J1
Zucali, PA1
Rinck, JA1
Zeppellini, A1
Bastos, DA1
Aurilio, G1
Mota, A1
Trindade, K1
Ortega, C1
Sade, JP1
Rizzo, M1
Vau, N1
Giannatempo, P1
Barillas, A1
Monteiro, FSM1
Dauster, B1
Cattrini, C1
Nogueira, L1
de Carvalho Fernandes, R1
Seront, E1
Aceituno, LG1
Grillone, F1
Cutuli, HJ1
Fernandez, M1
Bassanelli, M1
Roviello, G1
Abahssain, H1
Procopio, G1
Milella, M1
Kopecky, J1
Martignetti, A1
Messina, C1
Caitano, M1
Inman, E1
Kanesvaran, R1
Herchenhorn, D1
Santini, D1
Manneh, R1
Bisonni, R1
Zakopoulou, R1
Mosca, A1
Morelli, F1
Maluf, F1
Soares, A1
Nunes, F1
Pinto, A1
Zgura, A1
Incorvaia, L1
Ansari, J1
Zabalza, IO1
Landmesser, J1
Rizzo, A1
Mollica, V1
Sorgentoni, G1
Battelli, N1
Porta, C1
Bellmunt, J1
Santoni, M1
Zhang, X7
Hu, X3
Xie, Y1
Xie, L1
Chen, X2
Peng, M6
Li, D3
Deng, J5
Xiao, D3
Yang, X9
Wu, Y3
Zheng, Q1
Li, Y6
Wang, G1
Gao, S1
Yan, X1
Xie, J1
Wang, Y3
Sun, X3
Meng, X1
Yin, B1
Wang, B1
Molenaar, RJ1
van Hattum, JW1
Brummelhuis, IS1
Oddens, JR1
Savci-Heijink, CD1
Boevé, ER1
van der Meer, SA1
Witjes, JF1
Pollak, MN1
de Reijke, TM1
Wilmink, JW1
Dankner, R1
Roth, J1
Jang, JH1
Sung, EG1
Song, IH1
Lee, TJ1
Kim, JY1
Li, S2
Zhu, H1
Chen, H2
Xia, J1
Xu, R1
Lin, Q1
Wang, Z3
Ong, WYF1
Shen, T1
Sng, JH1
Lata, RM1
Mahendran, R1
Kesavan, E1
Chiong, E1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Neradilek, MB1
Wu, XT1
Zhang, D3
Huang, W1
Cui, Y2
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y3
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X3
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X8
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y6
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q4
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z4
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z2
Qian, J1
Ge, J1
Hu, J3
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T4
Wang, Q2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q3
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Wei, H1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J2
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X2
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
He, Z1
Chen, B1
Wu, J2
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J2
Shao, Z1
Yuan, C1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Zhou, S3
Xu, S2
Li, T1
Tao, T3
Tang, L1
Darko, KO2
He, S1
Zeng, Q2
Chen, AF2
Chen, JB1
Zhu, YW1
Ren, WB1
Liu, LF1
Chen, HQ1
Zu, XB1
Peng, J1
Rieken, M2
Xylinas, E2
Kluth, L2
Crivelli, JJ2
Chrystal, J2
Faison, T2
Lotan, Y2
Karakiewicz, PI2
Fajkovic, H2
Babjuk, M2
Kautzky-Willer, A1
Bachmann, A2
Scherr, DS2
Shariat, SF2
Sun, M1
Cresswell, J1
Guo, P3
Xiong, H1
Yu, X1
He, D2
Jin, X2
Valerón, PF1
de Pablos-Velasco, PL1
Mamtani, R1
Pfanzelter, N1
Haynes, K1
Finkelman, BS1
Keefe, SM1
Haas, NB1
Vaughn, DJ1
Lewis, JD1
Tseng, CH2
Gionfriddo, MR1
Morey-Vargas, OL1
Brito, JP1
Leppin, AL1
Murad, MH1
Montori, VM1
Suissa, S1
Azoulay, L1
Guo, LS1
Li, HX1
Li, CY1
Zhang, SY1
Wang, QL1
Gao, JM1
Liang, JQ1
Gao, MT1
Wu, YJ1
Nayan, M1
Bhindi, B1
Yu, JL1
Hermanns, T1
Mohammed, A1
Hamilton, RJ1
Finelli, A1
Jewett, MA1
Zlotta, AR1
Fleshner, NE2
Kulkarni, GS1
Pan, Q1
Yang, GL1
Yang, JH1
Lin, SL1
Liu, N1
Liu, SS1
Liu, MY1
Zhang, LH1
Huang, YR1
Shen, RL1
Gao, JX1
Bo, JJ1
Goossens, ME1
Buntinx, F1
Zeegers, MP1
Driessen, JH1
De Bruin, ML1
De Vries, F1
Li, L1
Xue, L1
Cheng, Y1
Lv, H1
Tao, X2
Ruiz-Tamayo, I1
Franch-Nadal, J1
Mata-Cases, M1
Mauricio, D1
Cos, X1
Rodriguez-Poncelas, A1
Barrot, J1
Coll-de-Tuero, G1
Mundet-Tudurí, X1
Yokoyama, NN1
Blair, CA1
Avizonis, D1
Wu, XR1
Uchio, E1
Youssef, R1
McClelland, M1
Pollak, M1
Zi, X2
Khajeh, NR1
Khoyilar, C1
Spradling, K1
Youssef, RF1
Yuan, W1
Tong, D1
Liu, G1
Lan, W1
Xiao, H1
Yang, J1
Sayyid, RK1
Peng, CY1
Xu, W1
Ahn, JH1
Jung, SI1
Yim, SU1
Kim, SW1
Hwang, EC1
Kwon, DD1
Brower, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer[NCT03379909]Phase 249 participants (Anticipated)Interventional2019-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for metformin and Urinary Bladder Neoplasms

ArticleYear
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
    BioMed research international, 2021, Volume: 2021

    Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm

2021
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review.
    Medicine, 2022, Nov-11, Volume: 101, Issue:45

    Topics: Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Metformin; Quality of Life; Urinary Bladder N

2022
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:2

    Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside H

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
    Medicine, 2018, Volume: 97, Issue:30

    Topics: Aged; Diabetes Mellitus, Type 2; Disease Progression; Disease-Free Survival; Female; Humans; Hypogly

2018
Novel application of metformin combined with targeted drugs on anticancer treatment.
    Cancer science, 2019, Volume: 110, Issue:1

    Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neopl

2019
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb

2013
Systematic reviews to ascertain the safety of diabetes medications.
    Current diabetes reports, 2014, Volume: 14, Issue:4

    Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractur

2014
Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts.
    Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemoprevention; Humans; Hydroxymeth

2018
Potential role for metformin in urologic oncology.
    Investigative and clinical urology, 2016, Volume: 57, Issue:3

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal

2016

Trials

3 trials available for metformin and Urinary Bladder Neoplasms

ArticleYear
Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer.
    BMC cancer, 2019, Nov-21, Volume: 19, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Biopsy; Cystoscopy; Drug Administration Schedule; Femal

2019
Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer.
    Singapore medical journal, 2022, Volume: 63, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Diabetes Mellitus; Disease Progre

2022
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

34 other studies available for metformin and Urinary Bladder Neoplasms

ArticleYear
Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PloS one, 2021, Volume: 16, Issue:9

    Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dichl

2021
Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
    BMC urology, 2022, May-24, Volume: 22, Issue:1

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Metformin; Phosph

2022
Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells.
    Disease markers, 2022, Volume: 2022

    Topics: Cell Line, Tumor; Cell Proliferation; Humans; Metformin; Phthalazines; Piperazines; Proto-Oncogene P

2022
Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta histochemica, 2023, Volume: 125, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Doxorubicin; Humans; Metformin; Urinary Bladder

2023
Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta histochemica, 2023, Volume: 125, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Doxorubicin; Humans; Metformin; Urinary Bladder

2023
Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta histochemica, 2023, Volume: 125, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Doxorubicin; Humans; Metformin; Urinary Bladder

2023
Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta histochemica, 2023, Volume: 125, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Doxorubicin; Humans; Metformin; Urinary Bladder

2023
Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Adult; BCG Vaccine; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycated He

2023
Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada.
    BMC urology, 2023, Jul-14, Volume: 23, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Cystectomy; Disease-Free Survival; Humans; Metformi

2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:11

    Topics: Carcinoma, Transitional Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Pro

2023
Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.
    Molecules (Basel, Switzerland), 2023, Sep-20, Volume: 28, Issue:18

    Topics: Administration, Intravesical; Animals; Chitosan; Disease Models, Animal; Hydrogels; Metformin; Mice;

2023
Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Journal of experimental & clinical cancer research : CR, 2019, Aug-27, Volume: 38, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Cell Cycle Checkpoints

2019
Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells.
    Anti-cancer drugs, 2020, Volume: 31, Issue:7

    Topics: Apoptosis; Apoptosis Inducing Factor; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Ce

2020
Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:18

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Culture Media;

2020
Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c/FASN axis.
    Signal transduction and targeted therapy, 2021, 03-01, Volume: 6, Issue:1

    Topics: Cell Line, Tumor; Clusterin; Fatty Acid Synthase, Type I; Humans; Lipogenesis; Metformin; Neoplasm P

2021
UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glycolysis;

2017
Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:5

    Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulat

2018
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
    BJU international, 2013, Volume: 112, Issue:8

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Disease Progression; Disease-Free Survival; Female; Foll

2013
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Urologic oncology, 2014, Volume: 32, Issue:1

    Topics: Aged; Carcinoma, Transitional Cell; Cause of Death; Cystectomy; Diabetes Mellitus; Female; Follow-Up

2014
Diabetes mellitus and non-muscle-invasive bladder cancer: not just a coincidence?
    BJU international, 2013, Volume: 112, Issue:8

    Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local;

2013
The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.
    International journal of molecular sciences, 2013, Dec-18, Volume: 14, Issue:12

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Depe

2013
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.
    Diabetes care, 2014, Volume: 37, Issue:7

    Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Huma

2014
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
    Acta diabetologica, 2014, Volume: 51, Issue:2

    Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglyce

2014
Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Anti-cancer drugs, 2014, Volume: 25, Issue:8

    Topics: AMP-Activated Protein Kinases; Apoptosis; Apoptosis Regulatory Proteins; CASP8 and FADD-Like Apoptos

2014
Metformin and cancer: mounting evidence against an association.
    Diabetes care, 2014, Volume: 37, Issue:7

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Sulfonylurea Compounds; Urinary Bladder

2014
Vitamin D3 enhances antitumor activity of metformin in human bladder carcinoma SW-780 cells.
    Die Pharmazie, 2015, Volume: 70, Issue:2

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Drug Synergism; Female; Humans; Hy

2015
The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Urologic oncology, 2015, Volume: 33, Issue:9

    Topics: Aged; Carcinoma, Transitional Cell; Cohort Studies; Cystectomy; Diabetes Mellitus; Disease-Free Surv

2015
Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.
    Journal of experimental & clinical cancer research : CR, 2015, Aug-07, Volume: 34

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival;

2015
Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce

2015
High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
    Oncotarget, 2016, Feb-23, Volume: 7, Issue:8

    Topics: Administration, Intravesical; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomark

2016
Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Diabetes Complications; Diabet

2016
High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:3

    Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent K

2016
Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Disease Progressio

2016
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
    Scientific reports, 2016, 06-23, Volume: 6

    Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Prol

2016
Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus.
    Journal of Korean medical science, 2016, Volume: 31, Issue:9

    Topics: Aged; Diabetes Mellitus, Type 2; Disease-Free Survival; Female; Glycated Hemoglobin; Humans; Kaplan-

2016
Illuminating the diabetes-cancer link.
    Journal of the National Cancer Institute, 2012, Jul-18, Volume: 104, Issue:14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic

2012
Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
    BMC cancer, 2013, Jan-04, Volume: 13

    Topics: Administration, Oral; Adult; Aged; Chi-Square Distribution; Diabetes Mellitus, Type 2; Humans; Hypog

2013